Prospective observational study of Japanese melanoma patients treated with combination therapy using nivolumab and ipilimiumab

Prospective observational study of Japanese melanoma patients treated with combination therapy using nivolumab and ipilimiumab - Nivo/Ipi Combi-POS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031736

Enrollment

100

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma, advanced

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced melanoma patients who have never treated with immune checkpoint inhibitors and planning to treat with nivolumab+ipilimumab combination therapy

Exclusion criteria

Exclusion criteria: Prior treatment with immune checkpoint inhibitors

Design outcomes

Primary

Measure	Time frame
Best overall response, overall surviva, adverse events	—

Countries

Japan

Contacts

Public ContactYasuhiro Fujisawa

University of Tsukuba Dermatology

fujisan@md.tsukuba.ac.jp0298533128

Outcome results